Interesting Images89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CTRosar, Florian MD∗; Bartholomä, Mark PhD∗; Maus, Stephan∗; Privé, Bastiaan M. MD†; Khreish, Fadi MD∗; Franssen, Gerben M. PhD†; Derks, Yvonne H.W. PhD†; Nagarajah, James MD, PhD†; Ezziddin, Samer MSc, MD, PhD∗ Author Information From the ∗Department of Nuclear Medicine, Saarland University, Homburg, Germany †Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands. Received for publication September 7, 2021; revision accepted December 30, 2021. Conflicts of interest and sources of funding: none declared. Correspondence to: Samer Ezziddin, MSc, MD, PhD, Department of Nuclear Medicine, Saarland University, Kirrberger Str, Geb. 50, D-66421 Homburg, Germany. E-mail: [email protected]. Clinical Nuclear Medicine: May 2022 - Volume 47 - Issue 5 - p 435-436 doi: 10.1097/RLU.0000000000004108 Buy Metrics Abstract For localization of biochemical recurrence of prostate cancer, 68Ga-PSMA-11 PET/CT imaging was performed in a 66-year-old man with no suspicious findings at 1 hour p.i. Additional 89Zr-PSMA-617 PET/CT revealed a small local recurrence in the prostate bed, facilitating consecutive local therapy. This interesting image points to the potential of PET/CT with 89Zr-labeled PSMA ligands, for example, 89Zr-PSMA-617, for identifying the source of biochemical recurrence despite otherwise negative imaging including conventional PSMA PET/CT. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.